Effect of oxygen level on the enhancement of tumor response to radiation by perfluorochemical emulsions or a bovine hemoglobin preparation
- PMID: 1917627
- DOI: 10.1016/0360-3016(91)90737-o
Effect of oxygen level on the enhancement of tumor response to radiation by perfluorochemical emulsions or a bovine hemoglobin preparation
Abstract
Attempts to correct tumor hypoxia with oxygen-carrying solutions have used high concentrations of inspired oxygen (FiO2 100% or 95%). In the clinic, however, obtaining such high levels of FiO2 using mask ventilation in older patients or in children may be difficult. Since lower levels of FiO2 had not been previously tested, we examined the antitumor efficacy of FiO2 levels of 65, 85, and 95% breathed for 1 hr prior to and during irradiation used with the concentrated perfluorochemical emulsion F44E, the less concentrated emulsion, Fluosol-DA, or a new preparation consisting of purified bovine hemoglobin solution, PBHS. When tested in mice bearing the Lewis lung carcinoma with 2, 3, or 4 Gy daily for 5 days, daily Fluosol-DA produced only a small increase in the slope of the tumor growth delay versus irradiation alone, when used with 85% FiO2 (dose modifying factor [DMF] 1.3), but produced a DMF of 2.1 with 95% FiO2. Various concentrations of F44E (2, 4, or 8 g PFC/kg) each required a 95% FiO2 for full effect but the 8 g/kg dose had a discernable effect with an FiO2 of 65% and 85% (DMF 1.25 and 1.30, respectively). For PBHS, in contrast, a DMF of 1.6 was observed at 20% FiO2, but surprisingly this increased further to 2.1 with 95% FiO2. Further investigations of PBHS with irradiation demonstrated that daily administration of PBHS (12 ml/kg) 1 hr before single Xray fractions of 5, 10, 15, or 20 Gy with 20% FiO2 resulted in a DMF of 1.6-1.7 in the FSaIIC fibrosarcoma compared with irradiation alone when ascertained by tumor cell excision assay. These results indicate that to achieve maximum antitumor benefit with these oxygen-carrying solutions with radiation therapy, care must be taken to insure that FiO2 levels near 100% are achieved.
Similar articles
-
Perfluorochemical emulsions can increase tumor radiosensitivity.Science. 1984 Mar 2;223(4639):934-6. doi: 10.1126/science.6695191. Science. 1984. PMID: 6695191
-
Influence of scheduling, dose, and volume of administration of a perfluorochemical emulsion on tumor response to radiation therapy.Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):945-51. doi: 10.1016/0360-3016(90)90017-e. Int J Radiat Oncol Biol Phys. 1990. PMID: 2211263
-
Response of subpopulations of the FSall C fibrosarcoma to low dose x-rays and various potential enhancing agents.Anticancer Res. 1992 May-Jun;12(3):1029-33. Anticancer Res. 1992. PMID: 1622113
-
Use of perfluorochemical emulsions in cancer therapy.Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):875-82. doi: 10.3109/10731199209119734. Biomater Artif Cells Immobilization Biotechnol. 1992. PMID: 1391527 Review.
-
Perfluorochemical emulsions: oxygen breathing in radiation sensitization and chemotherapy modulation.Important Adv Oncol. 1992:39-59. Important Adv Oncol. 1992. PMID: 1582677 Review. No abstract available.
Cited by
-
Anesthesia Medications and Interaction with Chemotherapeutic Agents.Oncol Ther. 2021 Jun;9(1):121-138. doi: 10.1007/s40487-021-00149-1. Epub 2021 Apr 16. Oncol Ther. 2021. PMID: 33861416 Free PMC article. Review.
-
Artificial blood-hope and the challenges to combat tumor hypoxia for anti-cancer therapy.Med Biol Eng Comput. 2025 Apr;63(4):933-957. doi: 10.1007/s11517-024-03233-6. Epub 2024 Nov 30. Med Biol Eng Comput. 2025. PMID: 39614063 Review.
-
Tumor vascular status controls oxygen delivery facilitated by infused polymerized hemoglobins with varying oxygen affinity.PLoS Comput Biol. 2020 Aug 20;16(8):e1008157. doi: 10.1371/journal.pcbi.1008157. eCollection 2020 Aug. PLoS Comput Biol. 2020. PMID: 32817659 Free PMC article.
-
Microvascular studies on the origins of perfusion-limited hypoxia.Br J Cancer Suppl. 1996 Jul;27:S247-51. Br J Cancer Suppl. 1996. PMID: 8763890 Free PMC article.
-
Identification of Critical Molecular Factors and Side Effects Underlying the Response to Thalicthuberine in Prostate Cancer: A Systems Biology Approach.Avicenna J Med Biotechnol. 2023 Jan-Mar;15(1):53-64. doi: 10.18502/ajmb.v15i1.11425. Avicenna J Med Biotechnol. 2023. PMID: 36789117 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous